ATRN-354 / Aprea - LARVOL DELTA

Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results (GlobeNewswire) - "Aprea Therapeutics...announced that it has acquired Atrin Pharmaceuticals Inc. ('Atrin') and reported financial results for the three months ended March 31, 2022....With the acquisition of the Atrin programs, Aprea intends to shift its primary focus to the ATR inhibitor ATRN-119, which will be studied as both a monotherapy and in combination with standard of care in Phase 1/2a clinical trials in solid tumor malignancies. In parallel with ATRN-119 development, Atrin initiated separate programs for a second-generation ATR inhibitor, ATRN-354, with potentially improved potency and pharmacokinetics, as well as for a potentially highly potent and selective WEE1 inhibitor - ATRN-W1051. These programs are expected to enter IND-enabling studies in 2022 and Aprea anticipates filing Investigational New Drug applications for these programs in 2023."

IND • M&A • Pipeline update • Trial status • Oncology • Solid Tumor